Arcturus Therapeutics Ltd (ARCT) Stock Price, Quote & News

Company Profile

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 900 2660

Website: arcturusrx.com

Address:

10628 Science Center Drive, Suite 250, San Diego, United States

wahoowa95 Sep. 17 at 2:11 AM

$ARCT its never too late to short! CF results will be out soon, dont you want a new car?

0 · Reply

neelsen01 Sep. 16 at 7:31 PM

$ARCT $17.50 Sept 19 puts yielding 5.7%…

1 · Reply

highnihilism Sep. 16 at 6:05 PM

IWM: Russell 2000 → $ARCT Arcturus Therapeutics $VSAT Viasat $TRTX TPG Re Finance Trust $VERX Vertex $GOSS Gossamer Bio

0 · Reply

SeeKingProphet Sep. 16 at 5:42 PM

$ARCT more manipulation from the market maker. They’re a real POS with this stock

0 · Reply

highnihilism Sep. 16 at 2:44 PM

Biotech → $MRNA Moderna $ARCT Arcturus Therapeutics $ABBV Abbvie $CRSP Crispr Therapeutics $AMGN Amgen

0 · Reply

Nganlm Sep. 16 at 5:46 AM

$ARCT An interesting article on mRNA therapeutics. https://www.pharmavoice.com/news/moderna-biontech-mrna-vaccines-drug-strand-therapeutics/760042/ Btw, short interest at 5.41M as of 29 August 2025, up from 5.14M on 15 August 2025.

0 · Reply

bigchouse Sep. 16 at 1:01 AM

$ARCT New price prediction due to expected 50bps cut from the Fed on Wednesday and positive news coming soon.

1 · Reply

Choice79 Sep. 16 at 12:06 AM

$ARCT 27k more shares for Kathy today.

0 · Reply

SeeKingProphet Sep. 15 at 11:33 PM

$ARCT so many bullish indicators it’s hard to count. I have calls, I have shares. This one is headed to $45 before you know it 🌋

0 · Reply

Smellmahass Sep. 15 at 7:56 PM

$ARCT Let me know if they drop news i think its worth a buy after the news.

1 · Reply

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Aug 11, 2025, 8:16 PM EDT - 5 weeks ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript

Aug 11, 2025, 4:01 PM EDT - 5 weeks ago

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

Jul 24, 2025, 4:01 PM EDT - 7 weeks ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jun 30, 2025, 11:00 AM EDT - 2 months ago

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Jun 23, 2025, 8:30 AM EDT - 3 months ago

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

May 12, 2025, 7:40 PM EDT - 4 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 4 months ago

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

Apr 22, 2025, 4:01 PM EDT - 5 months ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Apr 10, 2025, 8:00 AM EDT - 5 months ago

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Mar 6, 2025, 9:44 PM EST - 6 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:01 PM EST - 6 months ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Mar 5, 2025, 4:30 PM EST - 6 months ago

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Feb 24, 2025, 4:01 PM EST - 7 months ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Feb 14, 2025, 8:30 AM EST - 7 months ago

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Feb 4, 2025, 8:30 AM EST - 8 months ago

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Jan 31, 2025, 3:00 AM EST - 8 months ago

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Jan 30, 2025, 4:01 PM EST - 8 months ago

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 10, 2025, 8:00 AM EST - 8 months ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Jan 6, 2025, 4:01 PM EST - 9 months ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Dec 16, 2024, 4:01 PM EST - 9 months ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 18, 2024, 8:00 PM EST - 10 months ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 1:44 PM EST - 10 months ago

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14, 2024, 1:00 AM EST - 10 months ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 11, 2024, 4:01 PM EST - 11 months ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 7, 2024, 11:24 PM EST - 11 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 11 months ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Oct 31, 2024, 4:01 PM EDT - 11 months ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Sep 13, 2024, 8:15 AM EDT - 1 year ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Aug 27, 2024, 5:00 PM EDT - 1 year ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Aug 9, 2024, 5:27 AM EDT - 1 year ago

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 5, 2024, 8:50 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Jul 18, 2024, 7:30 PM EDT - 1 year ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Jul 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Jun 8, 2024, 2:42 AM EDT - 1 year ago

Arcturus: A Hidden Gem In The Biotech Sector

Jun 7, 2024, 10:30 AM EDT - 1 year ago

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

May 28, 2024, 6:30 AM EDT - 1 year ago

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

May 20, 2024, 8:30 AM EDT - 1 year ago

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

May 8, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Apr 25, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Apr 23, 2024, 6:01 AM EDT - 1 year ago

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis

Mar 7, 2024, 6:32 PM EST - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Feb 26, 2024, 9:00 AM EST - 1 year ago

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

Feb 22, 2024, 8:30 AM EST - 1 year ago

Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

wahoowa95 Sep. 17 at 2:11 AM

$ARCT its never too late to short! CF results will be out soon, dont you want a new car?

0 · Reply

neelsen01 Sep. 16 at 7:31 PM

$ARCT $17.50 Sept 19 puts yielding 5.7%…

1 · Reply

highnihilism Sep. 16 at 6:05 PM

IWM: Russell 2000 → $ARCT Arcturus Therapeutics $VSAT Viasat $TRTX TPG Re Finance Trust $VERX Vertex $GOSS Gossamer Bio

0 · Reply

SeeKingProphet Sep. 16 at 5:42 PM

$ARCT more manipulation from the market maker. They’re a real POS with this stock

0 · Reply

highnihilism Sep. 16 at 2:44 PM

Biotech → $MRNA Moderna $ARCT Arcturus Therapeutics $ABBV Abbvie $CRSP Crispr Therapeutics $AMGN Amgen

0 · Reply

Nganlm Sep. 16 at 5:46 AM

0 · Reply

bigchouse Sep. 16 at 1:01 AM

$ARCT New price prediction due to expected 50bps cut from the Fed on Wednesday and positive news coming soon.

1 · Reply

Choice79 Sep. 16 at 12:06 AM

$ARCT 27k more shares for Kathy today.

0 · Reply

SeeKingProphet Sep. 15 at 11:33 PM

$ARCT so many bullish indicators it’s hard to count. I have calls, I have shares. This one is headed to $45 before you know it 🌋

0 · Reply

Smellmahass Sep. 15 at 7:56 PM

$ARCT Let me know if they drop news i think its worth a buy after the news.

1 · Reply

EnigmaticFan Sep. 15 at 6:33 PM

$ARCT I’ve never seen implied volatility on options this high for ARCT, the market is expecting a large move.

3 · Reply

King316 Sep. 15 at 5:18 PM

$ARCT

2 · Reply

Smellmahass Sep. 15 at 5:11 PM

$ARCT Will buy or short after the data. Cant do a roulette play here.

1 · Reply

NetworkNewsWire Sep. 15 at 1:08 PM

Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth $OTLC $IOBT $SRPT $AUTL $ARCT https://ibn.fm/JJ36j

1 · Reply

MoneyGroupLLC Sep. 13 at 6:29 PM

Enter: $ARCT OCT 17 2025 $18 CALLS Buy in Price: $3.60 - $3.70 Take Profit: $4.68 Stop Bleeding: $3.17 ROI Potential: 30% Exit Within: 67 Minutes https://moneygroup.us/alerts

0 · Reply

Choice79 Sep. 13 at 4:31 AM

$ARCT Kathy picked up 25,000 shares today. Adding to her position.

1 · Reply

wahoowa96 Sep. 13 at 4:04 AM

$ARCT My Virology professor used to test us on exam ... what's the best way to protect us from HIV - a) self-abstinance, b) condom, c) vaccine. I know Charlie would pick a) self-abstinance and we can all laugh off...

0 · Reply

wahoowa96 Sep. 13 at 3:22 AM

$ARCT Charlie Kirk you good man. Rest in peace! https://youtu.be/joe1AiBPp0E?si=PhCa7_2MAtczXhJ7

0 · Reply

Eagley3k Sep. 13 at 1:12 AM

0 · Reply

Eagley3k Sep. 13 at 1:12 AM

$ARCT new position. ready for sep. news

2 · Reply

Dr_Feel_Good Sep. 12 at 7:17 PM

$ARCT we look to be filling da gap on the intraday.. was looking to nibble around $15 but if we recover from the lows letter ride.

0 · Reply

elmono Sep. 12 at 6:10 PM

$ARCT great …get to buy cheaper today 🙏 thank you

2 · Reply

Market Cap	492.32M
Revenue (ttm)	152.31M
Net Income (ttm)	-80.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-53.14%
Debt to Equity Ratio	0.00

Volume	927,400
Avg Vol	562,458
Day's Range	N/A - N/A
Shares Out	27.16M
Stochastic %K	58%
Beta	2.38
Analysts	Strong Sell
Price Target	$67.90